Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
777
datasets available to search
ShareScore release 0.7.1
Dataset results
777 results for “older patient”
Feasibility and Outcomes of Older Patients Hospitalization
ClinicalTrials.gov study NCT00489021. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Association of Preoperative Hippocampal Glucose Metabolism With Postoperative Delirium in Older Diabetic Patients
ClinicalTrials.gov study NCT07369466. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older
ClinicalTrials.gov study NCT00048503. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Predictive Model for Oropharyngeal Dysphagia in Non-hospitalized Older Patients
ClinicalTrials.gov study NCT05862142. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Food Intake in Older Patients
ClinicalTrials.gov study NCT02490761. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat
ClinicalTrials.gov study NCT06628713. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prognostic and Biologic Relevance of Clinically Applicable Long Non-Coding RNA Profiling in Older Patients with Cytogenetically Normal AML
GEO Series GSE130923. Homo sapiens. 99 samples. Type: Other.
Dataset related to article "The 70-year-old newly diagnosed glioblastoma patients are older thanthe 65-year-old? Outcome evaluation of the two categories in a matchedcase control study with propensity score balancing"
<p>This record contains raw data related to article “The 70-year-old newly diagnosed glioblastoma patients are older thanthe 65-year-old? Outcome evaluation of the two categories in a matchedcase control study with propensity score balancing"</p> <p>Background: The standard of care for elderly, newly-diagnosed glioblastoma patients consists, if feasible,</p> <p>of surgical resection followed by a short course of radiation therapy (RT) with concomitant and adjuvant</p> <p>temozolomide chemotherapy (TMZCHT). To date, the literature lacks of consistence in the definition of</p> <p>elderly, if older than 65 years, or 70 years. Aim of this study was to explore whether differences exist</p> <p>between these two cohorts, comparing outcomes using a propensity score matched analysis (PSM).</p> <p>Conclusions: The PSM analyses showed a similar outcome in 65–69-year old patients compared to older</p> <p>ones notwithstanding a more burdensome RT schedule. Hypofractionated RT treatment has to be considered</p> <p>also in this group of younger elderly, newly-diagnosed GBM patients.</p>
Dataset related to article "Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy "
<p>This record contains raw data related to article “Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy"</p> <p><strong>Introduction: </strong> Hepatocellular Carcinoma (HCC) is characterized, in Western countries, by higher incidence and mortality rates in the older adult population. In frail patients, limited therapeutic resources are available due to limited expected benefit concerning the risk of treatment-related toxicity. The aim of our study is to evaluate the role of Stereotactic Body Radiotherapy (SBRT) in the clinical management of older old adults (age ≥ 80 years) HCC patients and to identify predictors of efficacy and toxicity.</p> <p><strong>Material and methods: </strong> Clinical and treatment-related data of older old adults HCC patients treated with SBRT at our institution were retrospectively reviewed. Statistical analysis was carried out to identify variables correlated with impaired outcome and toxicity.</p> <p><strong>Results: </strong> Forty-two patients were included, accounting for 63 treated tumors. Median age was 85 (range 80-91) years. Median Charlson Comorbidity Index (CCI) and G8 scores were 10 (range 7-16) and 11 (range 8-14), respectively. SBRT was administered to a median BED10 of 103 Gy10. Median follow-up interval was 11 (range 3-40) months. Two years Local Control (LC), Progression-Free Survival (PFS), and Overall Survival (OS) were 93%, 31%, and 43%, respectively. Acute toxicity occurred in 28% (n = 13) of treatments. A G8 score > 10 was associated with improved survival (p = 0.045), while a CCI ≥10 was correlated with increased acute toxicity (p = 0.021).</p> <p><strong>Conclusions: </strong> SBRT is a safe and effective option in older old adults HCC patients. A comprehensive geriatric assessment (CGA) is advised before treatment decisions to select optimal candidates for SBRT.</p>
Dataset of the paper "Minimal detectable change of gait and balance measures in older neurological patients: estimating the standard error of the measurement from before-after rehabilitation data thanks to the linear mixed-effects models"
<p>The Excel file contains the dataset whose analysis has been presented in the manuscript entitled <em>"Minimal detectable change of gait and balance measures in older neurological patients: estimating the standard error of the measurement from before-after rehabilitation data thanks to the linear mixed-effects models" </em>and published in J Neuroeng Rehabil (doi: 10.1186/s12984-024-01339-4; PMID: 38566189).</p> <p>This data set cannot be publicly available because of sensitive information. Please send your request to: a.caronni@auxologico.it.</p>
Dataset related to: "Predictive factors of functional abilities in older patients with peripheral neuropathy"
<p>We provide the raw data used for the following article:</p> <p>Gialanella B, Prometti P, Comini L, Monguzzi V, Santoro R. <strong>Predictive factors of functional abilities in older patients with peripheral neuropathy.</strong> Aging Clin Exp Res. 2022 Jan;34(1):193-199. doi: 10.1007/s40520-021-01910-2. </p> <p>Abstract</p> <p><strong>Background and aims: </strong>Little is known about the outcome predictors in peripheral neuropathy (PN). This prospective observational study aimed to identify possible factors predicting the functional abilities in older patients with PN undergoing motor rehabilitation.</p> <p><strong>Methods: </strong>Data were collected in 80 PN patients, aged over 65 years, performing a standard inpatient motor rehabilitation program. The total Functional Independence Measure (FIM) score after rehabilitation, as well as efficiency and effectiveness in total-FIM, were the outcome measures. Backward multiple regression analyses identified the predictors of functional status.</p> <p><strong>Results: </strong>At the end of rehabilitation, total-FIM score was 102.66 ± 10.75, efficiency in total-FIM 0.64 ± 0.29 and effectiveness in total-FIM 48.81 ± 15.35%. Katz index at admission was a predictor of the final total-FIM score (beta 0.46, p < 0.001) and efficiency in total-FIM (beta - 0.38, p = 0.001). Conversely, age was a predictor of the final total-FIM score (beta - 0.31, p = 0.002) and effectiveness in total-FIM (beta - 0.49, p < 0.001). The R<sup>2</sup> values of the models were, respectively, 0.39, 0.15, and 0.24.</p> <p><strong>Discussion: </strong>In PN patients, functional impairment at admission and age are important predictors of functional abilities at the end of rehabilitation.</p> <p><strong>Conclusions: </strong>These findings suggest the need for more intensive rehabilitation in older, more disabled PN patients because they risk achieving lower functional levels with standard rehabilitation programs.</p>
Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis
ClinicalTrials.gov study NCT03278314. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Biomarkers in older ovarian cancer patients
GEO Series GSE126308. Homo sapiens. 50 samples. Type: Expression profiling by array.
Data set from Mazzaccaro D, Modafferi A, Malacrida G, Nano G. Assessment of long-term survival and stroke after carotid endarterectomy and carotid stenting in patients older than 80 years. J Vasc Surg. 2019 Aug;70(2):522-529. doi: 10.1016/j.jvs.2018.10.121. Epub 2019 Mar 2. PMID: 30837178.
<p>Data set from Mazzaccaro D, Modafferi A, Malacrida G, Nano G. Assessment of long-term survival and stroke after carotid endarterectomy and carotid stenting in patients older than 80 years. J Vasc Surg. 2019 Aug;70(2):522-529. doi: 10.1016/j.jvs.2018.10.121. Epub 2019 Mar 2. PMID: 30837178.</p> <p> </p> <p>This is the abstract:</p> <p><strong>Objective: </strong> The objective of this study was to analyze preoperative risk factors affecting long-term survival and the occurrence of stroke in patients older than 80 years undergoing either carotid endarterectomy (CEA) or carotid artery stenting (CAS) for carotid stenosis.</p> <p><strong>Methods: </strong> Data of all consecutive patients treated from January 1999 to December 2017 were retrospectively reviewed and outcomes analyzed. Kaplan-Meier analysis was used to estimate long-term survival and the risk of stroke for both groups. Cox proportional hazards analysis was used to assess the relative risk of all-cause mortality and long-term stroke for patients in the presence of selected comorbidities, including preoperative symptoms, coronary artery disease, chronic renal failure, atrial fibrillation (AF), hypertension, diabetes mellitus, and dyslipidemia. A P value <.05 was considered statistically significant.</p> <p><strong>Results: </strong> A total of 473 patients older than 80 years (298 men [63%]) underwent either CEA (n = 178) or CAS. At 30 days, one patient died in the CEA group of unrelated causes; no deaths were recorded after CAS (0.6% vs 0%; P = .18). At 5 years, survival was 67.6% ± 4.9% after CEA and 90.2% ± 2.3% after CAS (P < .0001). The main cause of death after CEA and CAS was a neoplasm. Estimated freedom from any stroke at 5 years was 97.3% ± 0.5% after CEA and 93.2% ± 1.2% after CAS (P = .07). The presence of preoperative AF significantly affected long-term mortality after CAS (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.34-1.98; P = .04) as well as being classified as American Society of Anesthesiologists class 3 at evaluation of the preoperative anesthesiology risk. The presence of preoperative AF was the only factor that significantly affected the occurrence of long-term stroke after both CAS (HR, 2.28; 95% CI, 1.86-5.63; P = .001) and CEA (HR, 3.45; 95% CI, 2.29-8.19; P = .005).</p> <p><strong>Conclusions: </strong> Both CEA and CAS showed low 30-day mortality and any-stroke rates in patients older than 80 years. In the long term, survival was significantly better after CAS; however, deaths after CEA and CAS were mainly unrelated to the procedure. No significant differences were recorded in the occurrence of any stroke in the long term. The presence of preoperative AF significantly affected long-term survival after CAS as well as being classified as American Society of Anesthesiologists class 3 at evaluation of the preoperative anesthesiology risk. The presence of preoperative AF also significantly affected long-term risk of stroke after both CAS and CEA.</p> <p> </p>
Unveiling A Hidden Burden: Exploring Sarcopenia in Hospitalized Older Patients through Concordance and Cluster Analysis
Open the record for dataset details and reuse information.
Dataset related to article "Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study"
<p>This record contains raw data related to article "Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study"</p><p>Abstract</p><p><strong>Background: </strong>Glecaprevir and Pibrentasvir (G/P) determine high rates of sustained virological response (SVR) with optimal safety profile in patients with chronic hepatitis C virus (HCV) infection. The efficacy and safety of G/P in Caucasian patients aged 75 years and older have not been widely analysed.</p><p><strong>Methods: </strong>This is a retrospective multicentre real-world study enrolling all consecutive patients 75 years and older who received G/P between October 2017 and January 2022 at five referral centres in Italy. SVR was analysed by intention-to-treat (ITT) and per-protocol analyses (PP).</p><p><strong>Results: </strong>A total of 570 patients met the inclusion criteria and were analysed: mean age was 80 (75-97) years, 356 (62%) were females, 52% (298/570) had HCV-1, 44% (252/570) had HCV-2 and 137 (24%) patients had liver cirrhosis. Four hundred and sixty-three (81%) patients were taking at least one concomitant drug, with 144 (25%) taking ≥5 concomitant drugs. G/P was given for 8 weeks in 488 patients (86%). During treatment, 48 patients (8%) reported side effects, with 10 (2%) patients discontinuing treatment prematurely. Two patients developed treatment-unrelated serious adverse events. Overall, the SVR rate was 97.9% (558/570) by ITT analysis and 99.6% (558/560) by PP analysis. SVR rates remained consistently high among subgroup analysis stratified by genotype, treatment duration, fibrosis stage and concomitant medications.</p><p><strong>Conclusions: </strong>Treatment with G/P achieved 97.9% SVR rates in HCV patients older than 75 years of age. Safety was optimal with only 2% of patients discontinuing early.</p>
PREVALENCE AND CLINICAL OUTCOME OF MAIN ECHOCARDIOGRAPHIC AND HEMODYNAMIC HEART FAILURE PHENOTYPES IN A POPULATION OF HOSPITALIZED PATIENTS 70 YEARS OLD AND OLDER
<p><strong>BACKGROUND</strong>: Heart failure (HF) echocardiographic and hemodynamic categories are poorly characterized in the elderly. We aimed to evaluate the prevalence and clinical outcomes of echocardiographic and hemodynamic HF phenotypes in a consecutive series of hospitalized patients aged ≥70 years.</p> <p><strong>METHODS: </strong>All consecutive patients ≥70 years old discharged from the Internal Medicine Unit of our Hospital with a diagnosis of HF, between January and November 2020, entered this retrospective study. All patients underwent physical examination, complete blood tests, chest-X ray and transthoracic echocardiography. At 1-year follow-up, we evaluated the occurrence of the composite outcome of all‐cause mortality and re-hospitalization.</p> <p><strong>RESULTS</strong>: 261 patients (86.3±6.4 yrs, 60.9% women) were retrospectively analyzed. From the study group, 106 “old” (70-84 yrs) and 155 “oldest-old” (≥85 yrs) patients were separately analyzed. A total of 169 (64.7%) patients reported the composite outcome during follow-up: 41 (15.7%) died and 128 (49.0%) were re-hospitalized. At 1-year follow-up, survival analysis did not show any statistically significant difference between age groups (p = 0.31) and between HF echocardiographic categories (p=0.34), whereas HF patients with “cold-dry” phenotype had significantly poorer survival compared to the other hemodynamic subtypes (p<0.001). Male sex (HR 1.44, 95%CI 1.04-1.98), “cold-dry” phenotype (HR 3.90, 95%CI 1.73-8.77), high sodium level (HR 1.03, 95%CI 1.01-1.04) and low estimated glomerular filtration rate (eGFR) (HR 0.98, 95%CI 0.97-0.99) were independently associated with the outcome occurrence.</p> <p><strong>CONCLUSIONS: </strong>Male sex, “cold-dry” phenotype, high sodium level and low eGFR are the main adverse prognostic indicators over a mid-term follow-up in hospitalized patients aged ≥70 yrs.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.